Quizartinib Plus chemotherapy significantly improved overall survival compared to chemo
Doubling of median overall survival seen in QuANTUM-First results presented at EHA Presidential Symposium
Doubling of median overall survival seen in QuANTUM-First results presented at EHA Presidential Symposium
The new Oncology CRO will aim to drive faster execution and higher quality trial outcomes for Oncology sponsors.
Ipsen obtains an exclusive license to develop, manufacture and commercialize a pre-clinical stage METTL3-inhibitor programme
Subscribe To Our Newsletter & Stay Updated